Last updated on July 2019

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI


Brief description of study

This study is designed to provide long-term CDZ173 treatment, a selective PI3K inhibitor, to the patients with genetically activated PI3K, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were treated previously with PI3K inhibitors other than CDZ173. The study is open-label designed to establish the long-term safety, tolerability, efficay and pharmacokinetics of CDZ173 in the target population.

Clinical Study Identifier: NCT02859727

Find a site near you

Start Over